Udall Project 2 Aim 2A&C

Launched by UNIVERSITY OF MINNESOTA · Dec 12, 2022

Keywords

ClinConnect Summary

The Udall Project 2 Aim 2A&C clinical trial is studying how a specific brain stimulation treatment called deep brain stimulation (DBS) affects movement in people with Parkinson's disease. Researchers will use advanced technology from the Medtronic Percept™ PC DBS system to measure brain signals and observe how these signals relate to walking and balance during everyday activities. The goal is to better understand how brain activity influences movement, especially in the legs, and how this might help improve patient care.

To participate in this trial, individuals must already be receiving DBS therapy for Parkinson's and have the Medtronic Percept DBS system implanted for at least three months. However, people with certain conditions, like severe joint problems or significant cognitive impairment, may not be eligible. Participants will be monitored over four weeks, during which they can expect to engage in various activities and have their brain signals recorded. This study aims to provide insights that could lead to better treatments and management of Parkinson’s disease symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Receiving DBS therapy in GP for treatment of PD
• • Implanted with Medtronic Percept DBS system
• • At least 3 months since initial activation of the neurostimulator
• Exclusion Criteria:
• • history of musculoskeletal disorders that significantly affects the ability to perform the motor tasks in the specific experiment in question
• • history of dementia or cognitive impairment
• • other significant neurological disorder as determined by the PI
• • post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment
• • lack of capacity to consent (as identified by UBACC)